Résumé : The latest American recommendations on dyslipidemia management in cardiovascular prevention have raised several questions, due to inherent differences with our standard approaches. Among others, these new recommendations have eradicated the need for a LDL-choiesterol 'target' depending on the level of cardiovascular risk. Instead, they have proposed a strategy based on the extent of the relative reduction in LDL-choiesterol. Critical review of European and American recommendations reveals, however, more similarities than differences. Comparing these recommendations Invites us to rethink several aspects of our clinical practice while enhancing our motivation to the greatest benefit of our patients.